Emergent Biosolutions Receives a Buy from Chardan Capital

By Austin Angelo

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Emergent Biosolutions (NYSE: EBS) yesterday and set a price target of $47. The company’s shares closed yesterday at $27.80.

According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -32.9% and a 20.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Asterias Biotherapeutics, Synthetic Biologics Inc, and Ritter Pharmaceuticals.

Emergent Biosolutions has an analyst consensus of Moderate Buy, with a price target consensus of $37.

Emergent Biosolutions’ market cap is currently $1.12B and has a P/E ratio of 20.90. The company has a book value ratio of 1.6709.

Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EBS in relation to earlier this year. Earlier this month, Barry Labinger, the EVP, Biosciences Div. of EBS sold 3,376 shares for a total of $123,224.

Emergent BioSolutions, Inc. is a biopharmaceutical company, which focuses on the research, development, and manufacture of novel vaccines and related products for prophylactic and therapeutic use against common diseases and biological weapons of mass destruction. The company operates through the Biodefense and Biosciences business segments. The Biodefense segment focuses on vaccines and antibody therapies for use against the infectious disease anthrax. The Biosciences segment engages in protein therapies to treat certain types of cancer and vaccines for use against infectious diseases. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.